Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript

Ginkgo Bioworks (DNA) held its Q3 2025 earnings call, where CEO Jason Kelly outlined the company's strategic direction, emphasizing its mission to make biology easier to engineer. A key objective for 2026 is to deliver robotics and software for autonomous, on-prem labs to customers, expanding its tools business model through AI and automation. The call was set to address the impact of AI on biotechnology and how Ginkgo's tools are securing new deals, though specific Q3 financial results were not detailed in this introductory segment.

Analysis

Ginkgo Bioworks (DNA) held its Q3 2025 earnings call, where CEO Jason Kelly outlined a strategic vision centered on making biology easier to engineer. The company emphasized its commitment to leveraging AI models to impact biotechnology, positioning its proprietary tools to capitalize on this trend and secure new customer deals. This call focused on forward-looking objectives rather than specific Q3 financial metrics, which were not detailed in the provided segment.

A primary objective for 2026 involves the delivery of robotics and software for autonomous, on-prem labs directly to customer sites. This initiative expands Ginkgo's "tools business" model, integrating AI and automation to empower customers to run biological engineering processes independently. This strategic shift aims to embed Ginkgo's technology deeper into client operations, potentially increasing recurring revenue streams.

The company's optimistic tone, reflected in a 0.7 per-ticker sentiment for DNA, underscores its confidence in AI's transformative role within biotech. Ginkgo's strategy to provide AI-controlled automation for biological engineering positions it as a key enabler in the evolving bio-economy. The focus on new deals and customer site integration suggests a growth-oriented approach, albeit with inherent risks associated with forward-looking statements.

Key Decisions for Investors

• Monitor progress on the 2026 autonomous lab objective, as successful implementation could significantly expand Ginkgo's market penetration and recurring revenue potential.
• Evaluate the company's ability to convert its AI and automation strategy into tangible new customer deals and sustained revenue growth, given the forward-looking nature of the guidance.
• Investors should review the full Q3 2025 financial results and SEC filings for detailed performance metrics and risk factors, which were not provided in this preliminary segment.